Research in Brief [0.03%]
研究速递
Holly Baker
Holly Baker
Bridging gaps in surgical care for neuroendocrine tumours: CUTNETs begins [0.03%]
填补神经内分泌肿瘤治疗的缺口：CUTNETs项目启动
Julie Hallet,Massimo Falconi,Stefano Partelli;CUTNETs collaborators
Julie Hallet
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis - Authors' reply [0.03%]
关于代谢紊乱相关肝硬化治疗的DEFEND研究——作者答复
George Kemble,Katharine Grimmer,Eduardo Bruno Martins et al.
George Kemble et al.
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis [0.03%]
用于治疗与代谢紊乱相关的肝炎的药物研发状态
Ziwei Gao,Wei Ye,Jingru Song
Ziwei Gao
Denifanstat for the treatment of metabolic dysfunction-associated steatohepatitis [0.03%]
用于治疗与代谢紊乱相关肝炎的药物 dennisfanstat
Xincheng Li,Ibrahim Ayada,Pengfei Li et al.
Xincheng Li et al.
The case for reducing the use of diagnostic upper and lower gastrointestinal endoscopy [0.03%]
关于减少诊断性上、下消化道内镜使用的思考
Christopher J Black,Alexander C Ford
Christopher J Black
No easy way out: blocking lymphocyte egress by the S1P1 receptor 1 modulator tamuzimod in ulcerative colitis [0.03%]
无退路可选：S1P1受体调节剂Tamuzimod通过阻断淋巴细胞输出治疗溃疡性结肠炎
Raja Atreya,Markus F Neurath
Raja Atreya
Tamuzimod in patients with moderately-to-severely active ulcerative colitis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 induction trial [0.03%]
溃疡性结肠炎患者的诱导治疗：一项关于塔木齐莫德的多中心双盲随机安慰剂对照二期临床试验
Bruce E Sands,Remo Panaccione,Geert D&#x;Haens et al.
Bruce E Sands et al.
Background: Tamuzimod (VTX002) is a selective sphingosine 1-phosphate receptor 1 modulator in development for ulcerative colitis. We aimed to assess the safety and efficacy of tamuzimod in patients with moderately-to-seve...
Elizabeth A Spencer
Elizabeth A Spencer
Maintenance treatment with vedolizumab in paediatric inflammatory bowel disease (VEDOKIDS): 54-week outcomes of a multicentre, prospective, cohort study [0.03%]
vedolizumab维持治疗在儿科炎症性肠病患者中的疗效和安全性：一项多中心前瞻性队列研究的第54周结果
Ohad Atia,Zivia Shavit-Brunschwig,Raffi Lev-Tzion et al.
Ohad Atia et al.
Background: Infliximab and adalimumab are the only biologics thus far approved for paediatric patients with inflammatory bowel disease (IBD), so other biologics, such as vedolizumab, are prescribed off-label. Despite its ...